iTeos Therapeutics Inc.

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

The decision by iTeos Therapeutics to wind down operations just a couple of weeks after the failure of its anti-TIGIT antibody belrestotug rather than hold on to considerable cash reserves until a buy

The TIGIT class claimed its latest casualty as iTeos Therapeutics’ belrestotug failed to show sufficient benefit in trials of patients with non-small cell lung cancer (NSCLC) and head and neck cancer,

Once a key part of its next-generation plans in cancer, Merck & Co . has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets. The two immu